First test of potential blood disorder drug in chinese volunteers
NCT ID NCT06581627
Summary
This early study tested a new medicine called etavopivat, which is being developed for sickle cell disease and thalassemia. It involved 24 healthy Chinese volunteers to see how their bodies process a single dose of the drug and to check for any side effects. The main goal was to understand the drug's safety and how it moves through the bloodstream in this specific population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.